Epstein-Barr Virus Implicate

For decades, scientists, and clinicians have known that systemic lupus erythematosus (SLE), has a complex origin involving genetics, hormones, and environmental influences. But the environmental triggers that tip the immune system into the self-destructive state characteristic of lupus have remained evasive. The leading suspect has been the Epstein-Barr virus (EBV), which is something nearly all humans carry.

Recent research has not only reinforced the association between EBV and lupus but has provided compelling evidence for a mechanistic link explaining how this virus might drive autoimmune function.

*Disclaimer:

The information provided in this article is for general informational purposes only and is not intended as medical advice. It should not be used as a substitute for professional diagnosis, treatment, or advice from a qualified healthcare provider. Reliance on any information provided in this article is solely at your own risk.

See a word you don't understand? Find it in our glossary.

EBV is a member of the herpesvirus family and one of the most common viruses in humans: more than 90% of adults worldwide have been infected by adulthood. It is known as the cause of mononucleosis (“mono”), a self-limiting illness characterized by fever, fatigue, sore throat, and lymphadenopathy. After initial infection, EBV enters a dormant (latent) state within B cells, which are white blood cells that are important to adaptive immunity. In most people, EBV remains latent and controlled by the immune system throughout life. Although EBV by itself is mostly harmless, scientists have suspected that EBV may play a direct role in triggering autoimmune diseases, including lupus.

Epidemiological research over the years has consistently shown:

• People with lupus generally have higher levels of antibodies to EBV proteins than healthy controls, suggesting increased or poorly coordinated viral activity.

• EBV DNA is more frequently detected in patients with lupus than in the general population.

• Meta-analyses of multiple studies show that prior EBV infection is a significant risk factor for developing lupus.

These stark associations pointed to a possible relationship but didn’t explain why or how EBV might instigate the autoimmune process. A major breakthrough came with research published in Science Translational Medicine showing that EBV can directly reprogram a subset of B cells in lupus patients, turning them into drivers of autoimmunity.

Researchers at Stanford and collaborating institutions found that:

• EBV infects a rare subset of B cells that are autoreactive, meaning they can recognize and react against the body’s own tissues.

• In lupus patients, these EBV‑infected B cells have abnormal ene expression patterns that resemble antigen‑presenting cells (APCs).

• These reprogrammed B cells express markers and genes associated with heightened immune activity, such as CD27 and TBX21, making them more likely to trigger autoimmune cascades.

• A viral protein called EBNA2 (produced by EBV) acts as a switch that alters host gene expression and promotes inflammatory pathways

Given that EBV infects the vast majority of adults, a question pops up: Why do only a small fraction of people develop lupus? The answer, while still unclear, is probably a complex mix of:

• Genetic predisposition: Some HLA (human leukocyte antigen) haplotypes and other gene variants increase autoimmune risk.

• Immune regulation differences: Some people control latent EBV better than others.

• Epigenetic and environmental factors: Other exposures and immune insults can contribute

Essentially, EBV may be necessary but not enough, and a lot of other factors need to happen to push the immune system into autoimmunity.

This understanding of EBV’s role in lupus opens exciting possibilities. If EBV actively contributes to disease onset or flares, then antiviral drugs, therapies targeting EBV‑infected B cells, or strategies to neutralize viral proteins like EBNA2 might reduce disease activity or progression. Additionally, developing an EBV vaccine could, in theory, prevent the infection from ever occurring, potentially reducing the incidence of EBV‑triggered autoimmune diseases. However, these vaccines would probably need to be administered early before initiation of EBV exposure, and challenges remain in ensuring long‑term immunogenicity.

For decades, lupus was described as an autoimmune disease with unknown triggers. The evidence implicating EBV represents one of the most significant shifts in understanding the disease’s cause in modern medical history. While research is still unfolding and clinical applications are in early stages, these studies are reshaping how scientists think about autoimmune diseases and how they might be prevented or treated.

What is the link between Epstein-Barr virus and lupus? | Autoimmune Registry

New study confirms significant association between Epstein-Barr Virus infection and systemic lupus erythematosus | Lupus Foundation of America

Epstein-Barr virus infection and its association with systemic lupus erythematosus: Systematic review and meta-analysis | NIH

Epstein-Barr virus protein can “switch on” risk genes for autoimmune diseases | NIH